Back

U7 small nuclear RNA splice-switching therapeutics for STMN2 and UNC13A in Amyotrophic Lateral Sclerosis

Mehta, P. R.; Solomon, T.; Pickles, S.; Harley, P.; Barioglio, M.; Schweingruber, C.; Marrero-Gagliardi, A.; Gao, Y.; Mattedi, F.; Barattucci, S.; Lin, L. T.-W.; Ryadnov, E.; Zanovello, M.; Cammack, A. J.; Isaacs, A.; Burrone, J.; Shaw, C. E.; Keuss, M. J.; Petrucelli, L.; Fratta, P.; Ruepp, M.-D.

2025-11-30 neuroscience
10.1101/2025.11.26.690143 bioRxiv
Show abstract

TDP-43 nuclear depletion in amyotrophic lateral sclerosis (ALS) causes de-repression of cryptic exons (CEs) in multiple transcripts, including UNC13A and STMN2, disrupting synaptic transmission and neurite outgrowth. We developed a therapeutic U7 snRNA (tU7) approach that suppresses TDP-43-dependent mis-splicing, restores target gene expression, rescues neuronal functions in human iPSC-derived neurons, and shows target engagement in vivo, positioning tU7-mediated splicing correction as a promising therapeutic strategy for ALS.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.